Introduction

Menopause is a natural stage of life, but the physical changes that accompany it can affect sleep, energy, body composition, skin, bone health, and overall quality of life. As estrogen levels decline, some women experience hot flashes, night sweats, disrupted sleep, changes in body-fat distribution, reduced muscle mass, and changes in skin elasticity.

These concerns have contributed to growing interest in peptide therapy for menopause. Peptides are short chains of amino acids that participate in biological signaling, and some peptide-based medicines have established medical uses. Others are being investigated for their potential effects on tissue repair, collagen production, growth hormone signaling, and cellular function.

The challenge is separating scientific research from marketing claims.

Peptides such as GHK-Cu, CJC-1295, Ipamorelin, sermorelin, and BPC-157 are frequently discussed in wellness and longevity circles. However, evidence that a compound influences a biological pathway does not establish that it relieves hot flashes, improves menopausal sleep, restores hormonal balance, or prevents age-related muscle loss.

Currently, there is insufficient high-quality clinical evidence to recommend these experimental or investigational peptides as treatments for menopause symptoms. Established menopause treatments have a substantially stronger evidence base for specific symptoms and medical indications. [1, 2]

This guide examines what peptide therapy involves, why certain peptides attract attention during menopause, what the evidence supports, and which safety considerations deserve attention.

What Is Peptide Therapy?

Peptides are short chains of amino acids, the building blocks of proteins. In the human body, naturally occurring peptides can act as signaling molecules that influence processes such as hormone release, metabolism, immune activity, and tissue function.

Some medicines use peptides or peptide-like compounds to interact with specific biological pathways. Their effects depend on their molecular structure, the receptors they act on, their formulation, and how they are administered.

Peptide therapy is a broad term rather than a single standardized medical treatment. It can refer to approved prescription medicines, compounds being investigated in clinical trials, or products marketed for wellness and anti-ageing purposes.

These categories should not be treated as equivalent. A peptide medicine approved for one condition does not automatically have established benefits for menopause, and research involving one peptide cannot be generalized to all others.

How does peptide therapy differ from menopause hormone therapy?

Menopause hormone therapy addresses declining hormone levels by providing estrogen, with progestogen generally needed for people with a uterus to protect the uterine lining when systemic estrogen is used.

Peptides work through different mechanisms, depending on the specific compound. Some stimulate the release of other hormones, while others are studied for their potential influence on cellular signaling or tissue processes.

Consequently, peptide therapy should not be considered a direct replacement for estrogen or other established menopause treatments. The appropriate approach depends on the symptoms being treated, medical history, individual risk factors, and the evidence supporting each option. [1, 2]

Why Are Peptides Being Discussed for Menopause?

Menopause involves more than changes in reproductive hormones. The transition can coincide with changes in body composition, bone density, sleep, skin structure, and physical recovery.

These changes have prompted interest in compounds that might influence the biological processes associated with them.

1. Skin elasticity and collagen

Collagen is a structural protein that helps maintain skin firmness and elasticity. Changes in collagen production and skin structure can occur with ageing and hormonal changes.

Peptides studied for collagen-related pathways have therefore attracted attention in skincare and regenerative research. However, evidence for a topical ingredient or a laboratory effect does not establish that an injectable peptide reverses menopausal skin changes.

2. Muscle mass and body composition

Ageing and hormonal changes can coincide with declines in muscle mass and strength. Maintaining muscle becomes particularly important for mobility, physical independence, and metabolic health.

Some peptides are marketed for their effects on growth hormone signaling. However, increasing growth hormone or related biomarkers does not automatically translate into greater muscle strength, better physical function, or improved long-term health in menopausal women.

3. Sleep and recovery

Sleep disturbances are common during the menopause transition, sometimes because of night sweats and hot flashes. Other factors, including stress, mood changes, and sleep disorders, can also contribute.

Peptides that influence hormonal signaling are sometimes promoted for sleep or recovery. Yet robust human evidence showing that the commonly marketed experimental peptides reliably improve menopausal sleep is lacking.

4. Tissue maintenance and joint health

Connective tissue and joint health are important throughout adulthood. Some peptides are being investigated for their possible effects on tissue remodeling and repair.

However, research into tissue repair does not demonstrate that a peptide treats menopause-related joint discomfort or prevents musculoskeletal decline.

The key question for each proposed application is whether controlled human studies demonstrate meaningful improvements in symptoms, function, or health outcomes.

Common Peptides Marketed for Menopause: What Does the Research Say?

Several compounds appear frequently in discussions about menopause, longevity, and body composition. Their proposed applications and evidence differ, so they need to be assessed individually.

1. GHK-Cu: Skin Health and Collagen Research

GHK-Cu is a copper-binding tripeptide studied for its potential involvement in collagen production, skin biology, and tissue remodeling.

Its research history has made it a subject of interest in skincare, particularly in discussions about skin elasticity and visible signs of ageing.

Why it attracts interest during menopause

Changes in skin structure and collagen are common concerns during midlife. Because GHK-Cu has been investigated for its relationship with collagen and extracellular matrix processes, researchers have explored its potential relevance to skin health.

What the evidence shows

Much of the research on GHK-Cu involves laboratory experiments, preclinical models, or relatively limited studies. These findings provide a basis for further investigation but do not establish that injectable GHK-Cu reverses menopausal skin changes.

There is also insufficient evidence to recommend GHK-Cu as a treatment for hot flashes, sleep disturbances, hormonal changes, or other core menopause symptoms.

Safety considerations

Topical and injectable formulations have different risk profiles. Evidence concerning a skincare product cannot automatically be applied to an injectable formulation.

The US Food and Drug Administration (FDA) has identified potential safety concerns involving compounded injectable GHK-Cu, including issues related to peptide impurities, aggregation, and limited human safety data. [3]

2. CJC-1295 and Ipamorelin: Growth Hormone Signaling

CJC-1295 and Ipamorelin are compounds that influence growth hormone signaling through different mechanisms. They are frequently discussed together in wellness contexts involving body composition, muscle maintenance, and recovery.

Why they attract interest during menopause

Because muscle mass and body composition can change with age, compounds that influence growth hormone have attracted interest as potential approaches to maintaining lean tissue.

However, the biological rationale does not establish a menopause-specific benefit.

What the evidence shows

Human research has demonstrated that CJC-1295 can increase growth hormone and insulin-like growth factor 1 (IGF-1) levels. This establishes an effect on hormonal biomarkers, not proof of improved muscle strength, better sleep, or relief from menopause symptoms.

Robust clinical trials demonstrating that CJC-1295 combined with Ipamorelin improves menopausal outcomes are lacking.

Safety considerations

Growth hormone signaling can influence glucose regulation and other physiological processes. Potential concerns include fluid retention and changes associated with elevated IGF-1.

The FDA has also identified limited safety information and potential risks involving compounded CJC-1295 and Ipamorelin formulations. These concerns include possible immune reactions related to peptide impurities or aggregation, and serious adverse events have been reported in association with CJC-1295. [3]

These compounds should not be assumed to be safe or effective for menopause-related muscle loss or recovery simply because they influence growth hormone pathways.

3. Sermorelin: Stimulating Growth Hormone Release

Sermorelin is a synthetic analogue of growth hormone-releasing hormone. It acts on the pituitary gland to stimulate growth hormone release.

It is sometimes promoted in wellness settings for body composition, sleep, and age-related changes.

Why it attracts interest during menopause

Growth hormone is involved in several physiological processes, including fat metabolism and tissue regulation. This has encouraged interest in whether stimulating its release could support muscle maintenance or other aspects of ageing.

What the evidence shows

Evidence supporting sermorelin as a treatment for menopause symptoms is insufficient. Changes in growth hormone levels do not establish improvements in menopausal sleep, body composition, or quality of life.

Its regulatory status and approved uses must also be evaluated for the specific product and jurisdiction rather than inferred from its proposed mechanism.

Safety considerations

Interventions that stimulate growth hormone signaling can affect glucose metabolism and IGF-1 levels. Their safety depends on the compound, formulation, dose, and individual circumstances.

Sermorelin should not be treated as an established alternative to menopause hormone therapy or as a proven way to reverse age-related changes.

4. BPC-157: Tissue Repair Research

BPC-157 is an experimental peptide discussed in relation to tendon, ligament, muscle, and other tissue-repair processes.

Why it attracts interest during menopause

Joint discomfort and musculoskeletal changes can become more noticeable during midlife. This has contributed to interest in compounds marketed for recovery and tissue maintenance.

What the evidence shows

Most of the research on BPC-157 has involved laboratory or animal studies. High-quality human clinical evidence demonstrating that it treats tendon injuries, improves joint health, or relieves menopause-related symptoms is lacking.

It is therefore not appropriate to describe BPC-157 as a proven treatment for menopause-related joint pain or tissue degeneration.

Safety considerations

The safety of BPC-157 in humans is not adequately established. The FDA has identified concerns involving possible immunogenicity, peptide impurities, and limited safety-related information for proposed compounded uses. [3]

The absence of adequate human evidence means that both its potential benefits and its longer-term risks remain uncertain.

Can Peptide Therapy Restore Hormonal Balance During Menopause?

There is currently no convincing clinical evidence that the commonly marketed experimental peptides discussed above can restore the hormonal balance associated with menopause.

Menopause occurs as ovarian hormone production declines. Peptides that stimulate growth hormone release or influence collagen-related pathways act through different biological systems.

Even when a peptide changes a hormone level, that does not mean it restores estrogen or progesterone to premenopausal levels, nor does it establish that it relieves hot flashes, night sweats, vaginal dryness, or other symptoms.

Claims that peptide therapy can broadly “reset hormones” or reverse menopause should therefore be approached cautiously.

For people experiencing disruptive symptoms, a healthcare professional can assess whether menopause hormone therapy or a non-hormonal treatment is appropriate. Treatment decisions should be based on symptoms, medical history, contraindications, and individual preferences. [1, 2]

What Are the Risks of Peptide Therapy for Menopause?

The risks depend on the specific compound, its formulation, route of administration, and the quality of available evidence.

For many peptides promoted for anti-ageing or menopause-related purposes, there is insufficient human research to establish a reliable balance of benefits and risks.

Product quality and contamination

Injectable products require appropriate manufacturing, quality control, and sterility. Products obtained from poorly controlled sources may contain impurities, incorrect concentrations, or contaminants.

The FDA notes that compounded drugs are not FDA-approved and are not reviewed by the agency for safety, effectiveness, and quality before marketing. Compounding can serve legitimate medical needs, but it also carries risks. [4]

Unknown long-term effects

Short-term laboratory findings or small studies cannot reliably establish the long-term safety of a compound.

For experimental peptides, researchers may not know which populations could benefit, what dose would be appropriate, how long treatment could safely continue, or what happens after treatment stops.

Side effects and interactions

Potential effects vary by compound. Peptides that influence growth hormone pathways may affect glucose regulation and fluid balance. Injectable products may also cause local reactions or other complications.

Interactions with medicines and underlying health conditions may be insufficiently studied. A compound should not be considered safe simply because it resembles a naturally occurring molecule.

Misleading marketing claims

Be cautious of claims that a peptide will eliminate hot flashes, restore youthful hormone levels, reverse ageing, or deliver guaranteed improvements in muscle, sleep, or skin.

The more specific the claimed health benefit, the more important it is to look for controlled human studies measuring that outcome.

Evidence-Based Options for Managing Menopause Symptoms

For people seeking relief from menopause symptoms, established treatments offer a more reliable starting point than experimental peptide therapy.

The most appropriate option depends on the symptoms, medical history, and individual risk factors.

Menopause hormone therapy

Hormone therapy can help relieve symptoms such as hot flashes, night sweats, and vaginal dryness. In selected circumstances, it can also help prevent bone loss.

Treatment may involve estrogen alone or estrogen combined with a progestogen, depending on factors including whether the person has a uterus.

Hormone therapy is not suitable for everyone. Potential risks and benefits depend on the formulation, route of administration, age, time since menopause, and medical history. A healthcare professional can help determine whether it is appropriate. [1, 2]

Non-hormonal treatments

Some people cannot use hormone therapy or prefer a non-hormonal approach. Evidence-based options include certain prescription medicines for vasomotor symptoms, alongside approaches addressing sleep, mood, and other specific concerns.

Treatment should be matched to the symptom rather than relying on a single intervention to address every aspect of menopause.

Muscle, bone, and metabolic health

Regular resistance training, weight-bearing activity, adequate nutrition, and sufficient protein can support muscle and bone health during midlife.

Depending on individual needs, a clinician may also assess bone density, blood pressure, blood glucose, cholesterol, and other health indicators.

These measures do not replace medical treatment when it is needed, but they can form an important part of a long-term menopause health plan.

How to Evaluate Peptide Therapy Claims

If you are researching a peptide because of a menopause-related concern, consider the following questions before making a decision.

1. Has the compound been studied in menopausal women?

Research involving animals, laboratory cells, or unrelated populations may not predict its effects during menopause.

2. Was the outcome measured in a clinical trial?

A change in a hormone level or laboratory marker is not equivalent to a demonstrated improvement in sleep, hot flashes, muscle strength, or quality of life.

3. Is the product approved for the proposed use?

Approval for one condition does not establish that a product is approved for menopause symptoms. Regulatory status also varies between countries and formulations.

4. Is the safety information adequate?

Look for human safety data, information about contraindications, and a clear understanding of potential adverse effects.

5. Is there an established treatment for the symptom?

If a symptom has evidence-based treatment options, discuss those with a qualified healthcare professional before considering experimental approaches.

These questions can help separate legitimate scientific investigation from claims that go beyond the available evidence.

Frequently Asked Questions

Does peptide therapy work for menopause?

There is currently insufficient high-quality clinical evidence to recommend the commonly marketed experimental peptides discussed in this article as treatments for menopause symptoms. Some compounds have promising laboratory or preclinical findings, but these do not establish that they safely and effectively relieve symptoms in menopausal women.

Which peptides are marketed for menopause?

Common examples include GHK-Cu, CJC-1295, Ipamorelin, sermorelin, BPC-157, and thymosin beta-4-related compounds. They have different mechanisms and research backgrounds. None should be assumed to have proven benefits for menopause simply because it is promoted for skin health, recovery, muscle maintenance, or ageing.

Can peptides help with menopause-related skin changes?

Some peptides are studied for their effects on collagen and skin biology. However, evidence for particular topical ingredients or laboratory findings cannot automatically be applied to injectable formulations. The effectiveness of experimental peptides for reversing menopause-related skin changes has not been established through robust clinical trials.

Can peptide therapy improve sleep during menopause?

Sleep disturbances during menopause can have several causes, including night sweats, mood changes, and other sleep disorders. There is insufficient robust evidence to recommend the experimental peptides discussed here as established treatments for menopausal sleep problems.

Are peptides a replacement for menopause hormone therapy?

No. Peptides that influence growth hormone signaling or tissue-related pathways are not direct substitutes for estrogen or other established menopause treatments. A qualified healthcare professional can help identify an appropriate treatment based on the symptoms and individual medical history.

Are injectable peptides safe?

Safety varies by compound and formulation. For many experimental peptides, human safety data are limited. Injectable products also raise concerns about product identity, impurities, sterility, and contamination. Online availability does not establish that a product is safe or approved for human use.

The Bottom Line

Peptide therapy has attracted interest as a possible way to address skin changes, muscle loss, sleep disturbances, and other concerns associated with menopause. The science, however, is not yet strong enough to support broad claims that experimental peptides can restore hormonal balance or reliably relieve menopausal symptoms.

GHK-Cu is being investigated for collagen and tissue-related processes, while CJC-1295 and Ipamorelin influence growth hormone signaling. Other experimental compounds are discussed in relation to tissue repair. Each has a distinct research profile, and none should be assumed to offer established menopause-specific benefits without adequate clinical evidence.

For people experiencing symptoms that affect daily life, evidence-based menopause care remains the most appropriate starting point. A healthcare professional can help evaluate treatment options, including hormone therapy and non-hormonal alternatives, while accounting for individual risks and preferences.

Explore the Mars Health Co peptide collection to learn more about the compounds available and their potential applications. As research continues to evolve, it’s important to distinguish emerging scientific findings from established clinical evidence. Consult a qualified healthcare professional before considering any peptide for menopause-related concerns or other health goals.

Medical Disclaimer

This article is intended for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Experimental peptides should not be used to treat menopause symptoms without appropriate medical guidance. Product availability does not establish safety, effectiveness, or regulatory approval for a particular use. Consult a qualified healthcare professional to discuss symptoms and evidence-based treatment options.

References

[1] What Is Peptide Therapy for Menopause, and Should You Try It? — Article discussing the evidence, limitations, and safety concerns surrounding peptides marketed for menopause.
https://www.everydayhealth.com/menopause/what-is-peptide-therapy-for-menopause/

[2] US Food and Drug Administration. Menopause: Hormone Therapy and Non-Hormonal Treatments. Information on menopause symptoms, approved treatments, and treatment-related risks.
https://www.fda.gov/consumers/womens-health-topics/menopause

[3] US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. Information on potential safety concerns associated with certain compounded peptides, including CJC-1295, Ipamorelin, and GHK-Cu.
https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

[4] US Food and Drug Administration. Human Drug Compounding. Overview of the regulatory status and safety considerations of compounded medicines.
https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding

[5] American College of Obstetricians and Gynecologists. Compounded Bioidentical Menopausal Hormone Therapy. Clinical guidance on evidence, safety, and the use of compounded hormone preparations.
https://www.acog.org/clinical/clinical-guidance/clinical-consensus/articles/2023/11/compounded-bioidentical-menopausal-hormone-therapy